

CGT Exome v3.1.2

Patient Information		Sample Information		Clinic Information	
Unique pat id.:	0068870 - 15425508	Sample type:	Blood	Clinic:	WeFIV
Patient name:		Date of draw:	02/08/2021	Doctor:	FLORENCIA DATRI
Patient DOB:		Date of receipt:	05/08/2021		
Ethnic group:	Latin	Report date/time:	15/01/2025		13:21
Indication:	No family history				

TEST RESULTS

POSITIVE

The individual is carrier of:

McArdle disease

Gene :	PYGM	Allele:	Het
DNA Change:	NM_005609.3:c.1094C>T	Inheritance:	AR
Protein change:	p.Ala365Val	OMIM phenotype:	232600
Variant classification:	Pathogenic		

Methylmalonic aciduria, vitamin B12-responsive, type cblB

Gene :	MMAB	Allele:	Het
DNA Change:	NM_052845.3:c.584G>A	Inheritance:	AR
Protein change:	p.Arg195His	OMIM phenotype:	251110
Variant classification:	Pathogenic		

Schindler disease, type I

Gene :	NAGA	Allele:	Het
DNA Change:	NM_000262.2:c.973G>A	Inheritance:	AR
Protein change:	p.Glu325Lys	OMIM phenotype:	609241
Variant classification:	Pathogenic		

INTERPRETATION OF TEST RESULTS

Typically, a positive result does not have direct clinical consequences for the carrier individual. There is another normal gene copy for all positive autosomal recessive (AR) genes indicated in the table which provides normal biological information. The likelihood of transmission of the variant(s) to offspring is 50%, independent for each variant. If the partner, or gamete donor, screens negative for the pathogenic or likely pathogenic variants in the gene(s) included in the table for this patient, the reproductive risk would be reduced. Please note that family members may also carry the variant(s) reported here, and this information may be significant for them and their offspring.

If a patient and partner, or gamete donor, are both carriers of variants in the same gene associated with AR inheritance, there is a 25% chance that any child they have together would be affected. If a female patient is a carrier for an X-linked condition, there is a 50% chance that each of the reproductive couple's children would also be a carrier. Males would typically express symptoms of the condition, and females are typically unaffected or may display milder symptoms.

For genes with a negative test result, the risk of having children affected by the associated disorders decreases significantly compared to the general population. This also the case for a negative personal result when a reproductive partner or a gamete donor is a carrier for a pathogenic or likely pathogenic variant in one or more of the tested genes. However, due to test limitations associated with any genetic test, this low risk is not zero (see limitations section and informed consent form)

LOW COVERAGE VARIANTS

NEK1:NM_001199397.1:c.3616G>T;RECQL4:NM_004260.3:c.84+1G>A;RECQL4:NM_004260.3:c.82C>T;RECQL4:NM_004260.3:c.50_51dupCG;DYNC2H1:NM_001080463.1:c.5846delA;DLL3:NM_016941.3:c.534C>A;BLOC1S3:NM_212550.4:c.448delC;G P1BB:NM_000407.4:c.505_516dupGTGCTGCTGCTG. These variants have a coverage lower than 7X and it is not possible to determine if they are present or not in the sample (non-informative variants).

TEST DESCRIPTION

The Carrier Genetic Test (CGT) is a preconception DNA screening test that aims to identify individuals and couples at increased risk of conceiving children affected by a monogenic disease. Knowledge of this risk may influence a couple's decision to conceive or encourage the couple to adopt preventive measures, including preimplantation genetic testing for the at risk disease (PGT-M) prenatal genetic testing, or to use donated gametes. The multigene CGT interrogates thousands of DNA variants using a high-throughput technology (Next Generation Sequencing, NGS).

COMMENTS

None

TEST METHODOLOGY

1. DNA extraction from the biological sample. 2. Next Generation Sequencing of gene regions where known mutations are located (list available at <https://cgt.igenomix.com/diseases-list/>). 3. Raw data analysis using bioinformatics. QC parameters require that more than 99.7% of the tested variants have coverage greater than the minimum read depth (10x). 4. Complementary testing by other techniques for: a) SMN1 gene: exon 7 deletion; exon 7-8 deletion; b) CYP21A2 gene: frequent mutations (<https://cgt.igenomix.com/diseases-list/>); c) HBA1/HBA2 genes: frequent deletions (<https://cgt.igenomix.com/diseases-list/>); d) FMR1 gene: CGG repeat sizing (females only); e) DMD gene: frequent deletions and duplications (females only); f) F8 gene: intron 22 inversion (females only).

TEST LIMITATIONS

The CGT test only includes analysis of the specific variants included into the list at <https://cgt.igenomix.com/diseases-list/>, and no others. Therefore, the CGT test does not cover all monogenic diseases nor 100% of disease-causing mutations for each tested gene. The test does not include the analysis of conditions associated with mitochondrial DNA, multifactorial, digenic or dominant inheritance. The test does not detect large rearrangements (inversions, deletions and duplications more than 15 nucleotides), mutations located in regulatory regions or intronic regions outside the +/-3bp cut off or in low sequence coverage areas. DNA changes caused by trinucleotide repeat expansions are not detected, except those indicated in the methodology section. Finally, if our assessment of a variant fails to meet our QC parameters due to low coverage, a result for the variant(s) will not be issued. The analytical detection rate is higher than 99%. The clinical sensitivity varies among conditions (e.g.: for HEXB gene, 30% of affected patients are carriers of a 16 kb deletion that is not included in the test). The sensitivity for SMN1 is approximately 96% because point mutations or small ins/del are not analyzed and, for a normal result (2 copies detected), it is not possible to be certain that the two copies are each in one of the two alleles (non-carrier) or if both are in the same allele (cis) and no copies in the other (carrier).

A negative result for the variants included in CGT does not exclude the possibility of being a carrier. The presence of pseudogenes and/or rare polymorphisms and/or homopolymers may lead to false negative or false positive results. A negative result for the CGT variants does not exclude the possibility of a de novo mutation being present in the offspring. Germline mosaicism or low-level somatic mosaicism cannot be detected. As with any laboratory test, there is a small chance that this result may be inaccurate for a procedural reason such as an error during sample collection, labelling, processing, data collection or interpretation. Please note that the classification of variants can change over time. To check whether there have been any changes to the classification of reported variants, please contact IGENOMIX.

LEGAL/QUALITY

IGENOMIX ARGENTINA S.A will only release the report once a completed test requisition form is received. The clinic/clinician/certified health professional requesting the test is responsible for obtaining and taking custody of "Informed Consent" from the patient as depicted by national guidelines and/or legislation. This test was developed, and its performance characteristics determined by IGENOMIX SPAIN LAB, SLU. It has not been cleared or approved by the US Food and Drug Administration. The test is used as a laboratory developed test for clinical purposes.

Part of this test has been outsourced to a reference laboratory whose Quality Management System is based on high Quality Standards, periodically monitored by Igenomix SPAIN* and audited by independent external groups.

*IGENOMIX SPAIN holds CLIA Certificate of Compliance: #99#D2146167.

EXEMPTION CLAUSE OF DIAGNOSTIC LIABILITY

The genetic diagnosis services carried out by IGENOMIX ARGENTINA S.A are exclusively intended to be interpreted by qualified/certified health professionals.

The result obtained by this test and the information that could be derived from it, cannot be considered in any case as substitute of genetic counselling or medical treatment by a trained professional neither represent itself a medical enquiry. We recommend that you consult your physician for genetic testing & counselling upon reception of your results.

Any result should be interpreted in the context of all available clinical findings, within the general context of a medical investigation, which must be conducted by clinically trained professionals. IGENOMIX ARGENTINA S.A is not responsible for any decisions made or actions undertaken by the contracting party based on the results provided by IGENOMIX ARGENTINA S.A or otherwise., nor the harmful temporary consequences diverted by its use, making specific discretion of taking appropriate legal measures assuming an improper use of those mentioned studies and analysis.

SIGNED



Camila Ayala Lira da Cruz
CRBIO 113163
Bióloga

COUNTERSIGNED



Arantxa Hervas PhD
3025-CV
Biotechnologist

This test or part of this test has been outsourced to a referral Laboratory. Lab CLIA No.: 99D2146167

McArdle disease

What is McArdle disease?

McArdle disease follows an autosomal recessive pattern of inheritance and is caused by pathogenic variants in the PYGM gene located on chromosomal region 11q13.1. The age of onset is infantile. This disease is characterized by muscular exercise intolerance with myalgia, cramps, fatigue, and muscle weakness.

What is the next step if I am a carrier of McArdle disease?

If you are a carrier of McArdle disease it is important that your partner (or gamete donor) is tested to determine if she/he is also a carrier of this condition.

What if my partner isn't a carrier?


If your partner tests negative for McArdle disease, the possibility of having an affected child is very low, significantly lower than the incidence of disease in the general population. However, there is not a test capable of detecting all existing pathogenic variants. Therefore, a residual risk remains of having unknown or undetectable pathogenic variants using current technology.

What if both parents are carriers of McArdle disease?

When both parents are carriers of McArdle disease, the probability of having a child with the disease is 25% in each pregnancy. (See graph)

What if I am going to use gamete donation?

In this case it is advisable to use the same assay (CGT) to test candidate donors and choose one that is negative for the same condition.



If both are carriers of the disease contact your doctor or genetic counselor for information on genetic options for family planning.



Methylmalonic aciduria, vitamin B12-responsive, type cblB

What is Methylmalonic aciduria, vitamin B12-responsive, type cblB?

Vitamin B12-responsive methylmalonic acidemia type cbl B follows an autosomal recessive pattern of inheritance and is caused by pathogenic variants in the MMAB gene located on chromosomal region 12q24.31. The age of onset is early infantile. This disease is characterized by developmentally delayed with other features that include hypotonia, seizures, hypoglycaemia, metabolic acidosis, cardiomyopathy and diarrhoea. The prevalence is <1:1,000,000.

What is the next step if I am a carrier of Methylmalonic aciduria, vitamin B12-responsive, type cblB?

If you are a carrier of Methylmalonic aciduria, vitamin B12-responsive, type cblB it is important that your partner (or gamete donor) is tested to determine if she/he is also a carrier of this condition.

What if my partner isn't a carrier?


If your partner tests negative for Methylmalonic aciduria, vitamin B12-responsive, type cblB, the possibility of having an affected child is very low, significantly lower than the incidence of disease in the general population. However, there is not a test capable of detecting all existing pathogenic variants. Therefore, a residual risk remains of having unknown or undetectable pathogenic variants using current technology.

What if both parents are carriers of Methylmalonic aciduria, vitamin B12-responsive, type cblB?

When both parents are carriers of Methylmalonic aciduria, vitamin B12-responsive, type cblB, the probability of having a child with the disease is 25% in each pregnancy. (See graph)

What if I am going to use gamete donation?

In this case it is advisable to use the same assay (CGT) to test candidate donors and choose one that is negative for the same condition.



If both are carriers of the disease contact your doctor or genetic counselor for information on genetic options for family planning.



Schindler disease, type I

What is Schindler disease, type I?

Schindler disease follows an autosomal recessive pattern of inheritance and is caused by pathogenic variants in the NAGA gene located on chromosomal region 22q13.2. The age of onset is infantile. This disease is characterized by early-onset neuroaxonal dystrophy and neurological signs (convulsion during fever, epilepsy, psychomotor retardation and hypotonia). NAGA deficiency is typically classified in three main phenotypes: NAGA deficiency type I (Schindler disease or Schindler disease type I) with severe manifestations; NAGA deficiency type II (Kanzazi disease or Schindler disease type II) which is mild; NAGA deficiency type III (Schindler disease type III) characterized by mild-to-moderate neurologic manifestations. NAGA deficiency results in the increased urinary excretion of glycopeptides and oligosaccharides containing alpha-N-acetylgalactosaminyl moieties.

What is the next step if I am a carrier of Schindler disease, type I?

If you are a carrier of Schindler disease, type I it is important that your partner (or gamete donor) is tested to determine if she/he is also a carrier of this condition.

What if my partner isn't a carrier?


If your partner tests negative for Schindler disease, type I, the possibility of having an affected child is very low, significantly lower than the incidence of disease in the general population. However, there is not a test capable of detecting all existing pathogenic variants. Therefore, a residual risk remains of having unknown or undetectable pathogenic variants using current technology.

What if both parents are carriers of Schindler disease, type I?

When both parents are carriers of Schindler disease, type I, the probability of having a child with the disease is 25% in each pregnancy. (See graph)

What if I am going to use gamete donation?

In this case it is advisable to use the same assay (CGT) to test candidate donors and choose one that is negative for the same condition.



If both are carriers of the disease contact your doctor or genetic counselor for information on genetic options for family planning.



GLOSSARY

TYPES OF INHERITANCE:

- **AR: Autosomal recessive**
Inherited conditions that require two pathogenic variants (one from each parent) in a given gene to display symptoms.
- **XR: X-linked recessive**
The gene is located on the X chromosome. Men with a pathogenic variant have the disease. Women with a pathogenic variant are carriers and generally asymptomatic or may mild symptoms.
- **Digenic inheritance**
In some diseases, the symptoms could be explained by the coexistence of pathogenic variants in two different genes related with the disease instead of two pathogenic variants in the same gene.

ALLELES:

Pathogenic variants present in the two copies of a gene.

- **Homozygous pathogenic variant (Hom.):**
Each copy of the gene has the same pathogenic variant. Generally, this is associated with clinical symptoms.
- **Compound heterozygous (Het.):**
Each copy of the gene has a different pathogenic variant. Generally, this is associated with clinical symptoms. This situation is referred as having variants "in trans".

Pathogenic variant present in one copy of a gene.

- **Heterozygous pathogenic variant (Het.):**
Only one copy of a gene has a pathogenic variant. There is another normal gene copy.

Note: Sometimes an individual has two pathogenic variants in the same gene copy. This situation is referred as having variants in cis and it is considered as a single pathogenic variant.

CNV:

Refers to copy number variation (deletion or duplication), i.e., the number of copies of a particular gene (or gene region) is different from the usual two copies.

LARGE GENE CONVERSION:

Refers to pathogenic variants caused by gene sequence exchange or replacement between a normal functional gene and a quasi-identical non-functional gene (pseudogene).